Liraglutide
Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) developed as an acylated analogue of the endogenous incretin hormone GLP-1.
Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) developed as an acylated analogue of the endogenous incretin hormone GLP-1. Originally approved for the management of type 2 diabetes mellitus (under the trade name Victoza) and subsequently for chronic weight management (Saxenda), liraglutide exerts its primary pharmacological effects by binding to and activating the GLP-1 receptor (Glucagon-like peptide-1 receptor (GLP-1R)), a G protein-coupled receptor expressed in pancreatic beta cells, the central nervous system, and multiple peripheral tissues. Receptor activation stimulates cAMP production and downstream signaling through cAMP-dependent protein kinase catalytic subunits, leading to glucose-dependent insulin secretion, suppression of glucagon release, delayed gastric emptying, and reduction of food intake. Its fatty acid side chain confers a plasma half-life of approximately 13 hours, enabling once-daily subcutaneous administration. The molecule exists in a pH-dependent oligomeric equilibrium in solution, a biophysical property with implications for formulation stability and drug delivery.
Beyond its established metabolic indications, liraglutide has emerged as a pleiotropic therapeutic agent with demonstrated or investigated activity across neuropsychiatric, oncological, neurodegenerative, and organ-protective domains. Its structural similarity to other clinically deployed GLP-1RAs, including semaglutide, and to the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist tirzepatide, has made it a key comparator in mechanistic studies probing the shared and divergent biological activities of this drug class. Active investigation of novel delivery systems, particularly oral formulations, reflects ongoing efforts to broaden accessibility and patient adherence beyond the injectable route.
Where the papers sit
16 papers from the last 6 months study liraglutide directly · updated from PubMed 16 Nov 2026
Study type 1 clinical trial · 2 observational · 2 human data · 8 preclinical · 3 unclassified
Themes 3 themes
-
GLP-1 Pharmacology and Clinical Effects
GLP-1R activation is being examined for appetite control, delayed gastric emptying, body weight and obesity treatment. Clinical studies address adolescents, post-bariatric patients and background glucose-lowering therapy, while experimental studies examine gut microbiota, gut-brain signaling and the brain-kidney axis. Protein studies instead track oligomer interconversion and fibril dissociation. The shared subject is broad drug biology, with no single clinical or mechanistic direction dominating.
8 papers · 50%
-
Metabolic and Cardiovascular Benefits
Liraglutide’s metabolic effects are expanding from weight and glucose control toward macrophage and tissue remodeling. In obese type 2 diabetes, altered cholesterol handling, ATP-binding cassette subfamily A member 1 and H3K27ac are linked to M2 polarization; liver slices show HSC deactivation and ECM remodeling. Cardiovascular analyses test whether LEADER findings transport to real-world populations, while adolescent studies examine appetite after sleeve gastrectomy. Oral insulin–liraglutide nanoparticles represent an effort to improve delivery.
5 papers · 31.2%
-
Diabetic Organ Injury Protection
Diabetic organ injury is being targeted through liraglutide-based anti-inflammatory and mitochondrial protection. In heart injury, sinomenine plus liraglutide restores mitochondrial homeostasis and suppresses CASP1/NLRP3-associated pyroptosis. Lung and muscle protection involves TLR4/NF-κB and Atrogin-1/AMPK signaling, while kidney studies test liraglutide with dapagliflozin. The evidence remains preclinical and centered on streptozotocin-diabetic rat models.
3 papers · 18.8%
Papers
The 16 papers from the last 6 months that study liraglutide directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
GLP-1 Pharmacology and Clinical Effects (8)
- Treatment With a GLP-1 Receptor Agonist Versus Reduction of the Gastrojejunal Anastomosis Diameter Using Endoscopic Argon Plasma Coagulation for Recurrent Weight Gain After Roux-en-Y Gastric Bypass. Obesity surgery · 27 Sept 2026 PMID 42802300
- A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in Taiwan. Obesity research & clinical practice · 15 Sept 2026 PMID 42744726
- Monitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy. Analytical chemistry · 8 Sept 2026 PMID 42708757
- Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes. Diabetes research and clinical practice · 10 Aug 2026 PMID 42575344
- A clinical and experimental investigation of liraglutide effects on the brain-kidney axis. Science advances · 5 Aug 2026 PMID 42555711
- Effects of liraglutide on gut bacterial community dynamics. Microbiology spectrum · 3 Aug 2026 PMID 42545022
- Appetite Suppression by GLP-1 Receptor Agonists: Role of Delayed Gastric Emptying. Obesity (Silver Spring, Md.) · 2 Jul 2026 PMID 42392577
- Microbiota-driven gut-brain signaling underlies antidepressant effects of a GLP-1 analog. Cell host & microbe · 10 Jun 2026 PMID 42269582
Metabolic and Cardiovascular Benefits (5)
- Liraglutide ameliorates obese type 2 diabetes by regulating macrophage cholesterol metabolism and H3K27ac modification to promote M2 polarization and adipocyte thermogenic activation. Journal of molecular histology · 13 Oct 2026 PMID 42870021
- Real-world cardiovascular effects of liraglutide: transportability analysis of the LEADER trial. American journal of epidemiology · 22 Sept 2026 PMID 42768735
- Effects of Liraglutide on Energy Intake in Adolescents With Persistent Obesity After Vertical Sleeve Gastrectomy. Pediatric obesity · 1 Aug 2026 PMID 42538646
- Development of zein-based nanoparticles for oral co-delivery of insulin and liraglutide and preliminary in vivo evaluation in Danio rerio. International journal of biological macromolecules · 13 Jul 2026 PMID 42442575
- Microfluidic human liver slices reveal antifibrotic effects of liraglutide via HSC deactivation and ECM remodeling. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2 Jul 2026 PMID 42392029
Diabetic Organ Injury Protection (3)
- A Novel Dual Therapy for Diabetic Ischemic Heart Injury: Sinomenine and Liraglutide Restore Mitochondrial Homeostasis and Suppress Pyroptosis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 19 Sept 2026 PMID 42762056
- Evaluation of the protective effects of liraglutide, dapagliflozin and their combination in rat kidneys of streptozotocin induced diabetes. Journal of diabetes and its complications · 24 Jun 2026 PMID 42341385
- Liraglutide ameliorates diabetic lung injury and muscle damage via modulation of TLR4/NF-κB and Atrogin-1/AMPK signaling pathways. Molecular biology reports · 26 May 2026 PMID 42189284
By study type
Clinical trials (1)
- Appetite Suppression by GLP-1 Receptor Agonists: Role of Delayed Gastric Emptying. Obesity (Silver Spring, Md.) · 2 Jul 2026 PMID 42392577
Observational studies and case reports (2)
- Treatment With a GLP-1 Receptor Agonist Versus Reduction of the Gastrojejunal Anastomosis Diameter Using Endoscopic Argon Plasma Coagulation for Recurrent Weight Gain After Roux-en-Y Gastric Bypass. Obesity surgery · 27 Sept 2026 PMID 42802300
- Changes in recorded background glucose-lowering therapy after initiation of a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in adults with type 2 diabetes. Diabetes research and clinical practice · 10 Aug 2026 PMID 42575344
Human data, design not indexed (2)
- Effects of Liraglutide on Energy Intake in Adolescents With Persistent Obesity After Vertical Sleeve Gastrectomy. Pediatric obesity · 1 Aug 2026 PMID 42538646
- Microfluidic human liver slices reveal antifibrotic effects of liraglutide via HSC deactivation and ECM remodeling. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2 Jul 2026 PMID 42392029
Preclinical: animal, cell and lab studies (8)
- Liraglutide ameliorates obese type 2 diabetes by regulating macrophage cholesterol metabolism and H3K27ac modification to promote M2 polarization and adipocyte thermogenic activation. Journal of molecular histology · 13 Oct 2026 PMID 42870021
- A Novel Dual Therapy for Diabetic Ischemic Heart Injury: Sinomenine and Liraglutide Restore Mitochondrial Homeostasis and Suppress Pyroptosis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 19 Sept 2026 PMID 42762056
- Monitoring Liraglutide Oligomeric Interconversion and Fibril Dissociation through High-Pressure NMR Spectroscopy. Analytical chemistry · 8 Sept 2026 PMID 42708757
- A clinical and experimental investigation of liraglutide effects on the brain-kidney axis. Science advances · 5 Aug 2026 PMID 42555711
- Effects of liraglutide on gut bacterial community dynamics. Microbiology spectrum · 3 Aug 2026 PMID 42545022
- Development of zein-based nanoparticles for oral co-delivery of insulin and liraglutide and preliminary in vivo evaluation in Danio rerio. International journal of biological macromolecules · 13 Jul 2026 PMID 42442575
- Evaluation of the protective effects of liraglutide, dapagliflozin and their combination in rat kidneys of streptozotocin induced diabetes. Journal of diabetes and its complications · 24 Jun 2026 PMID 42341385
- Liraglutide ameliorates diabetic lung injury and muscle damage via modulation of TLR4/NF-κB and Atrogin-1/AMPK signaling pathways. Molecular biology reports · 26 May 2026 PMID 42189284
Unclassified: not yet indexed with MeSH (3)
- Real-world cardiovascular effects of liraglutide: transportability analysis of the LEADER trial. American journal of epidemiology · 22 Sept 2026 PMID 42768735
- A multicenter real-world study on the safety and effectiveness of the glucagon-like peptide-1 receptor agonist (liraglutide) in adolescents with obesity in Taiwan. Obesity research & clinical practice · 15 Sept 2026 PMID 42744726
- Microbiota-driven gut-brain signaling underlies antidepressant effects of a GLP-1 analog. Cell host & microbe · 10 Jun 2026 PMID 42269582
Written from 16 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-24 by GPT. Corrections: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.